Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
9.33
|
9.97
|
8.51
|
8.31
|
10.29
|
9.59
|
|
|
3 648 698.82
|
3 051.00
|
8.05
|
8.39
|
8.30
|
8.10
|
8.89
|
8.46
|
|
|
1 620 750.25
|
2 966.00
|
8.23
|
9.00
|
9.09
|
8.09
|
9.36
|
8.23
|
|
|
2 199 027.92
|
3 376.00
|
8.70
|
9.06
|
9.77
|
9.00
|
9.97
|
9.09
|
|
|
1 208 311.40
|
2 332.00
|
9.89
|
10.05
|
8.22
|
8.1829
|
10.16
|
10.00
|
|
|
2 276 092.21
|
2 578.00
|
8.20
|
8.60
|
8.53
|
8.20
|
8.7794
|
8.46
|
|
|
2 341 902.50
|
2 801.00
|
8.40
|
8.83
|
9.50
|
7.80
|
10.12
|
8.47
|
|
|
6 290 197.47
|
7 198.00
|
10.75
|
11.07
|
9.78
|
9.05
|
9.865
|
9.50
|
|
|
3 371 510.18
|
3 699.00
|
9.50
|
11.66
|
9.56
|
9.25
|
10.27
|
9.82
|
|
|
3 130 584.62
|
4 120.00
|
9.30
|
11.66
|
9.52
|
9.06
|
9.98
|
9.51
|
|
|
2 935 296.56
|
4 039.00
|
Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.